MCID: LKM004
MIFTS: 37

Leukemia, B-Cell, Chronic

Categories: Rare diseases, Blood diseases, Immune diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Leukemia, B-Cell, Chronic

MalaCards integrated aliases for Leukemia, B-Cell, Chronic:

Name: Leukemia, B-Cell, Chronic 49
Chronic Lymphocytic Leukemia 69
Chronic B-Cell Leukemia 49

Classifications:



Summaries for Leukemia, B-Cell, Chronic

MalaCards based summary : Leukemia, B-Cell, Chronic, also known as chronic lymphocytic leukemia, is related to leukemia, chronic lymphocytic and leukemia, chronic lymphocytic 2, and has symptoms including fatigue, edema and chest pain. An important gene associated with Leukemia, B-Cell, Chronic is ATM (ATM Serine/Threonine Kinase). The drugs Methotrexate and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Leukemia, B-Cell, Chronic

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Leukemia, B-Cell, Chronic via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 11.7
2 leukemia, chronic lymphocytic 2 10.2
3 leukemia 10.1
4 richter's syndrome 9.7

Symptoms & Phenotypes for Leukemia, B-Cell, Chronic

UMLS symptoms related to Leukemia, B-Cell, Chronic:


fatigue, edema, chest pain, angina pectoris

Drugs & Therapeutics for Leukemia, B-Cell, Chronic

Drugs for Leukemia, B-Cell, Chronic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 580)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
4
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
5
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 439693 40926
6
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 21704 32326
7
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
8
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
9
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
10 Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
11
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
13
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
14
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
16 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
20 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
21 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
25 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
26 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
35 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
39 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
40 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
42 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Bendamustine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1691)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
3 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4 Valganciclovir
4 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
5 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Completed NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
6 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4 chlorambucil;cyclophosphamide;fludarabine;rituximab [MabThera]
7 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
8 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4 Ofatumumab
9 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
10 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4 Epoetin alfa
11 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
12 Low Grade Lymphoma Recruiting NCT01698866 Phase 4
13 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
14 A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Not yet recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
15 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4 Epoetin Beta
16 A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia Withdrawn NCT01739491 Phase 4 No intervention
17 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
18 Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
19 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
20 A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
21 The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3 Cholecalciferol;oleum neutralicum
22 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
23 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
24 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
25 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
26 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
27 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
28 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
29 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
30 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
31 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
32 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
33 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
34 Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
35 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
36 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
37 Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
38 FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
39 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3 Bendamustine at a dose of 100 mg/m2;Bendamustine at a dose of 120 mg/m2
40 Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
41 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
42 A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
43 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
44 Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia Completed NCT00281892 Phase 3 Fludarabine mono
45 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3
46 Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
47 Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
48 Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate
49 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
50 Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia Completed NCT00645606 Phase 3

Search NIH Clinical Center for Leukemia, B-Cell, Chronic

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Leukemia, B-Cell, Chronic

Anatomical Context for Leukemia, B-Cell, Chronic

MalaCards organs/tissues related to Leukemia, B-Cell, Chronic:

38
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Kidney, Nk Cells

Publications for Leukemia, B-Cell, Chronic

Articles related to Leukemia, B-Cell, Chronic:

(show top 50) (show all 2875)
# Title Authors Year
1
Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study. ( 29444501 )
2018
2
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation. ( 29450641 )
2018
3
Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia. ( 29315075 )
2018
4
Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patients. ( 29449436 )
2018
5
Composite Lymphoma as Co-occurrence of Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Carrying Trisomy 12 and t(14;18) and Peripheral T-cell Lymphoma. ( 29415977 )
2018
6
Highly similar genomic landscapes in monoclonal B-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations. ( 29449433 )
2018
7
Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL). ( 29437555 )
2018
8
Cerebral aspergillosis: An emerging opportunistic infection in patients receiving ibrutinib for chronic lymphocytic leukemia? ( 29402474 )
2018
9
Disseminated cerebral toxoplasmosis in a patient with chronic lymphocytic leukemia. ( 29428267 )
2018
10
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28073846 )
2017
11
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
12
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. ( 28639485 )
2017
13
Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia. ( 28931525 )
2017
14
Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders. ( 28893099 )
2017
15
S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-I_B activity during disease progression. ( 28596424 )
2017
16
Chronic Lymphocytic Leukemia: Individualizing Treatment Approach. ( 28515252 )
2017
17
Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. ( 27757836 )
2017
18
Venetoclax for the treatment of patients with chronic lymphocytic leukemia. ( 28492339 )
2017
19
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. ( 28517553 )
2017
20
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. ( 28924241 )
2017
21
Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. ( 28192408 )
2017
22
Hemorrhagic pericardial effusion as the debut of acquired hemophilia in a chronic lymphocytic leukemia patient: A case report, and a review of acquired hemophilia A-related hematological malignancies. ( 29381944 )
2017
23
Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting. ( 28824637 )
2017
24
Wnt5a induces ROR1 to associate with 14-3-3IP for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. ( 28465528 )
2017
25
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. ( 28499646 )
2017
26
Infectious complications in chronic lymphocytic leukemia- a retrospective analysis: single institution experience. ( 28503927 )
2017
27
NF-I_B p50 (nfkb1) contributes to pathogenesis in the EI1-TCL1 mouse model of chronic lymphocytic leukemia. ( 28515090 )
2017
28
Tumor Protein 53 Gene Mutations Without 17p13 Deletion Have No Significant Clinical Implications in Chronic Lymphocytic Leukemia. Detection of a New Mutation. ( 28476805 )
2017
29
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. ( 28091403 )
2017
30
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ ATM FISH deletions. ( 28493833 )
2017
31
Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia. ( 28833505 )
2017
32
Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients. ( 28699185 )
2017
33
HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia. ( 27859015 )
2017
34
Intravascular large B-cell lymphoma presenting as Richter's syndrome with cerebral involvement in a patient with chronic lymphocytic leukemia. ( 28878900 )
2017
35
NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. ( 28321119 )
2017
36
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. ( 28495642 )
2017
37
The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling. ( 28982149 )
2017
38
Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28514780 )
2017
39
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. ( 28062113 )
2017
40
Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. ( 28465529 )
2017
41
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. ( 28077600 )
2017
42
Treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting simultaneously with acquired hemophilia and warm autoimmune hemolytic anemia. ( 28670081 )
2017
43
Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. ( 28160756 )
2017
44
State of the Art in MicroRNA as Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia. ( 28084621 )
2017
45
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. ( 29296799 )
2017
46
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. ( 28526063 )
2017
47
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. ( 28935694 )
2017
48
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. ( 28718694 )
2017
49
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions. ( 28903342 )
2017
50
The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia. ( 28083607 )
2017

Variations for Leukemia, B-Cell, Chronic

Expression for Leukemia, B-Cell, Chronic

Search GEO for disease gene expression data for Leukemia, B-Cell, Chronic.

Pathways for Leukemia, B-Cell, Chronic

GO Terms for Leukemia, B-Cell, Chronic

Sources for Leukemia, B-Cell, Chronic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....